A £10.5 million prostate cancer project led by a researcher at an Aberdeen university will use data to answer critical questions about the “under-researched” disease.
Prostate cancer is the most common cancer of men in Europe, representing one in 10 of all male cancer deaths.
It affects at least as many people and is as deadly as breast cancer, however, up until now has received far less research funding, and progress made in the field is limited compared to other major cancer types.
The PIONEER European Commission IMI-funded project, led by University of Aberdeen academic Professor James N’Dow, pictured, aims to plug the gaps in knowledge of the management and treatment of the disease.
He said: “PIONEER has the potential to create a real step change in the treatment of prostate cancer.
“Along with our collaborators we will co-ordinate a wide-ranging consultation with key stakeholders and collate and harmonise massive amounts of data already collected from prostate cancer patients to transform the field of prostate cancer care.”
Areas requiring further investigation within the project include insufficient knowledge of those at risk of developing prostate cancer and a lack of knowledge of patient characteristics including genetic profiles.